Pricing analysis is the preparation for price negotiations between pharmaceutical companies and the central federal association of health insurance funds. The goal is to achieve an economically viable and fair price for your company as well as finding a long-term business relationship with the sick funds.

We work together with recognized institutions and experts to provide a complete overview about decision models. We will show of potential risks and opportunities for your product. The reality within the German market is that a clinical study is not sufficient concerning duration & side effects but rather you must also show within health care policy context the cost of the system as well as the benefit to the patient.